Literature DB >> 16043003

Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases.

Edward Chow1, Lori Davis, Lori Holden, May Tsao, Cyril Danjoux.   

Abstract

To prospectively assess patient-rated symptoms in patients with brain metastases treated with whole brain radiotherapy, these patients were asked to rate their symptoms on the Edmonton Symptom Assessment Scale (ESAS) before, and 1, 2, 4, 8, and 12 weeks following the radiation treatment. ESAS evaluates pain, fatigue, nausea, depression, anxiety, drowsiness, appetite, sense of well-being, and shortness of breath on a scale of 0-10 (0=absence of symptom and 10=worst possible symptom). Patients with a language barrier or significant cognitive impairment were excluded. The mean difference of ESAS symptoms at each follow up were compared with baseline and P < 0.01 was considered statistically significant. One hundred seventy patients (102 female and 68 male) were included between January 1999 and January 2002. Their median age was 66 years (range 33-84) and the median Karnofsky performance score (KPS) at baseline was 60 (range 20-90). The most common primary cancer sites were lung (99; 58%), breast (32; 19%), gastrointestinal (16; 9%), unknown (14; 8%) and others (9; 6%). One-third had significant weight loss (> or =10% over the last 6 months). All patients were prescribed dexamethasone at varying doses during radiotherapy. The dose fractionations were 20 Gy in 5 fractions, 138 (81%); 30 Gy in 10 fractions, 7 (4%); and others, 25 (15%). The baseline mean +/- SD for ESAS scores were: pain 2.4 +/- 2.8, fatigue 5.3 +/- 2.8, nausea 1.3 +/- 2.2, depression 2.8 +/- 2.7, anxiety 3.6 +/- 3.0, drowsiness 3.5 +/- 2.9, appetite 3.0 +/- 3.2, sense of well-being 3.8 +/- 2.7, and shortness of breath 2.3 +/- 2.5. For the entire cohort, after the delivery of palliative radiotherapy for brain metastases, there were statistically significant deteriorations in the mean differences from the baseline for the following ESAS domains: fatigue 1.0 to 1.8; drowsiness 1.2 to 1.8; and appetite 2.2 to 2.4. The data demonstrate that certain parameters of quality of life worsen after whole brain radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043003     DOI: 10.1016/j.jpainsymman.2005.02.009

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  35 in total

1.  The Brain Symptom and Impact Questionnaire in brain metastases patients: a prospective long-term follow-up study.

Authors:  Natalie Pulenzas; Saurabh Ray; Liying Zhang; Rachel McDonald; David Cella; Leigha Rowbottom; Arjun Sahgal; Hany Soliman; May Tsao; Cyril Danjoux; Breanne Lechner; Edward Chow
Journal:  CNS Oncol       Date:  2015-12-18

2.  Symptoms and quality of life in patients with brain metastases receiving whole-brain radiation therapy.

Authors:  Erin Wong; Liying Zhang; Leigha Rowbottom; Nicholas Chiu; Leonard Chiu; Rachel McDonald; May Tsao; Elizabeth Barnes; Cyril Danjoux; Edward Chow
Journal:  Support Care Cancer       Date:  2016-06-29       Impact factor: 3.603

3.  Symptom clusters using the Spitzer quality of life index in patients with brain metastases--a reanalysis comparing different statistical methods.

Authors:  Luluel Khan; Gemma Cramarossa; Madeline Lemke; Janet Nguyen; Liying Zhang; Emily Chen; Edward Chow
Journal:  Support Care Cancer       Date:  2012-07-18       Impact factor: 3.603

4.  A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.

Authors:  Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

Review 5.  The psychometric properties of cancer multisymptom assessment instruments: a clinical review.

Authors:  Aynur Aktas; Declan Walsh; Jordanka Kirkova
Journal:  Support Care Cancer       Date:  2015-04-19       Impact factor: 3.603

6.  The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.

Authors:  A Gabriella Wernicke; Menachem Z Yondorf; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; John A Boockvar; Susan Pannullo; Philip Stieg; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

7.  Does Graded Prognostic Assessment outperform Recursive Partitioning Analysis in patients with moderate prognosis brain metastases?

Authors:  Neil C Estabrook; Stephen T Lutz; Cynthia S Johnson; Simon S Lo; Mark A Henderson
Journal:  CNS Oncol       Date:  2016-03-17

8.  The Edmonton symptom assessment system--what do patients think?

Authors:  Sharon Watanabe; Cheryl Nekolaichuk; Crystal Beaumont; Asifa Mawani
Journal:  Support Care Cancer       Date:  2008-10-25       Impact factor: 3.603

9.  Symptom clusters in patients with advanced cancers.

Authors:  Winson Y Cheung; Lisa W Le; Camilla Zimmermann
Journal:  Support Care Cancer       Date:  2009-01-30       Impact factor: 3.603

Review 10.  The relationships between depression and brain tumors.

Authors:  N Scott Litofsky; Andrew G Resnick
Journal:  J Neurooncol       Date:  2009-03-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.